News By Tag Industry News News By Place Country(s) Industry News
| Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insights, 2015 - A DelveInsight’s ReportDelveInsight, the leading market research and consulting company has added a new report “Bile Duct Cancer - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight.
By: DelveInsight Business Research · 30+ pipeline drugs with 25+ companies actively involved in drug development. There is 1 drug in phase III, 14 in phase II, 10 in phase I, 2 in pre-clinical and 1 in discovery. · Concordia Healthcare is developing a lead product Porfimer Sodium which is in Phase III. · R&D activities and technologies used along with the pipeline molecules in development. · Stages of development of pipeline molecules. · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, Bile Duct Cancer (Cholangiocarcinoma) DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email at info@delveInsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
|